Workflow
Orient Securities
icon
Search documents
泰恩康(301263):首次覆盖报告:拐点将至,CKBA打开成长空间
Orient Securities· 2025-04-10 09:34
Investment Rating - The report gives the company an "Accumulate" rating for the first time, with a target price of 21.06 CNY based on a 54 times P/E ratio for 2025 [3][6]. Core Views - The company is expected to experience rapid progress in its core business or important products over the next 1-2 years, with projected earnings per share of 0.26, 0.39, and 0.62 CNY for 2024-2026 [3]. - The company has a solid foundation as a comprehensive pharmaceutical enterprise, having established a research and development platform and acquired a pipeline of high-potential products [10][15]. - The treatment for vitiligo is scarce, and the company's CKBA product is expected to stand out in the market due to its unique mechanism and promising clinical trial results [10][50]. Financial Information - The company's revenue for 2022 was 783 million CNY, with a projected revenue of 757 million CNY for 2024, followed by 951 million CNY in 2025 and 1,214 million CNY in 2026, reflecting a growth rate of 25.7% and 27.6% respectively [5]. - The net profit attributable to the parent company for 2022 was 175 million CNY, with projections of 111 million CNY for 2024, 165 million CNY for 2025, and 262 million CNY for 2026, indicating a significant growth trajectory [5]. - The gross margin is expected to improve from 58.6% in 2024 to 69.7% in 2026, while the net margin is projected to increase from 14.7% in 2024 to 21.6% in 2026 [5]. Business Overview - The company started as an agent and has developed into a comprehensive pharmaceutical enterprise, focusing on gastrointestinal, sexual health, and ophthalmic medications [10][15]. - The core products include "Hewei Zhengchang Wan" and "Woli Ting," with a strong emphasis on research and development to enhance product offerings [10][15]. - The company has significantly increased its R&D investment, leading to the successful development of key products like Dapoxetine and a rich pipeline of innovative drugs [32][34].
吉比特(603444):新游陆续上线贡献增量
Orient Securities· 2025-04-10 09:04
吉比特 603444.SH 公司研究 | 年报点评 | | 增持 (维持) | | --- | --- | | 股价(2025年04月08日) | 204.8 元 | | 目标价格 | 207.90 元 | | 52 周最高价/最低价 | 265.93/148.25 元 | | 总股本/流通 A 股(万股) | 7,204/7,204 | | A 股市值(百万元) | 14,754 | | 国家/地区 | 中国 | | 行业 | 传媒 | | 报告发布日期 | 2025 年 04 月 10 日 | | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现% | -9.3 | -10.18 | -0.24 | 18.78 | | 相对表现% | -3.21 | -2.74 | 3.41 | 15.55 | | 沪深 300% | -6.09 | -7.44 | -3.65 | 3.23 | | 项雯倩 | 021-63325888*6128 | | --- | --- | | 李雨琪 | xiangwenqian@orientsec. ...
云南白药2024年报点评:业绩强劲增长,业务结构优化
Orient Securities· 2025-04-10 05:23
公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 39,111 | 40,033 | 42,417 | 44,281 | 46,777 | | 同比增长 (%) | 7.2% | 2.4% | 6.0% | 4.4% | 5.6% | | 营业利润(百万元) | 4,831 | 5,712 | 6,050 | 6,653 | 7,328 | | 同比增长 (%) | 43.3% | 18.2% | 5.9% | 10.0% | 10.1% | | 归属母公司净利润(百万元) | 4,094 | 4,749 | 5,103 | 5,594 | 6,140 | | 同比增长 (%) | 36.4% | 16.0% | 7.5% | 9.6% | 9.8% | | 每股收益(元) | 2.29 | 2.66 | 2.86 | 3.14 | 3.44 | | 毛利率(%) | 26.5% | 27.9% | 28.9% | 29.4% | 29.8% | | ...
云南白药(000538):2024年报点评:业绩强劲增长,业务结构优化
Orient Securities· 2025-04-10 03:23
Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company has demonstrated strong performance growth and optimized its business structure, achieving a revenue of 40.03 billion yuan in 2024, a year-on-year increase of 2.4%, and a net profit attributable to the parent company of 4.75 billion yuan, up 16.0% year-on-year [9] - The report predicts earnings per share for 2025-2027 to be 2.86, 3.14, and 3.44 yuan respectively, with a target price of 62.92 yuan based on a 22x PE valuation for 2025 [3][6] Financial Information Summary - Revenue (million yuan): 2023A: 39,111, 2024A: 40,033, 2025E: 42,417, 2026E: 44,281, 2027E: 46,777 [5] - Year-on-year growth in revenue (%): 2023A: 7.2%, 2024A: 2.4%, 2025E: 6.0%, 2026E: 4.4%, 2027E: 5.6% [5] - Operating profit (million yuan): 2023A: 4,831, 2024A: 5,712, 2025E: 6,050, 2026E: 6,653, 2027E: 7,328 [5] - Year-on-year growth in net profit attributable to the parent company (%): 2023A: 36.4%, 2024A: 16.0%, 2025E: 7.5%, 2026E: 9.6%, 2027E: 9.8% [5] - Gross margin (%): 2023A: 26.5%, 2024A: 27.9%, 2025E: 28.9%, 2026E: 29.4%, 2027E: 29.8% [5] - Net margin (%): 2023A: 10.5%, 2024A: 11.9%, 2025E: 12.0%, 2026E: 12.6%, 2027E: 13.1% [5] - Return on equity (%): 2023A: 10.4%, 2024A: 12.1%, 2025E: 12.3%, 2026E: 11.9%, 2027E: 11.7% [5] - Price-to-earnings ratio: 2023A: 24.8, 2024E: 21.4, 2025E: 19.9, 2026E: 18.1, 2027E: 16.5 [5]
因子选股系列之一一二:ADWM:基于门控机制的自适应动态因子加权模型
Orient Securities· 2025-04-10 02:46
ADWM:基于门控机制的自适应动态因子 加权模型 ——因子选股系列之一一二 研究结论 自适应动态因子加权模型 金融工程 | 专题报告 为了克服市场状态市场风格发生突变时,短周期加权模型很有可能学习到错误的规律从 而造成巨大的回撤,我们设计了一套端到端因子生成和因子加权模型。该模型通过学习 市场上长期历史数据既捕捉 alpha 信息,又根据市场状态和个股属性信息学习 alpha 因子 的时变规律来对 alpha 因子进行加权,该模型框架由两部分组成: 各模型因子对比 根据输入的不同和加权方式的不同,我们提出了五个模型并进行对比,得到以下结论: 因子在各宽基指数上表现 风险提示 报告发布日期 2025 年 04 月 10 日 | 杨怡玲 | yangyiling@orientsec.com.cn | | --- | --- | | | 执业证书编号:S0860523040002 | | 陶文启 | taowenqi@orientsec.com.cn | | | 执业证书编号:S0860524080003 | ABCM:基于神经网络的alpha因子和beta 因子协同挖掘模型:——因子选股系列之 一一〇 2024- ...
美团-W:美团24Q4点评:核心主业好于预期,海外加大投入-20250410
Orient Securities· 2025-04-10 01:23
Investment Rating - The report maintains a "Buy" rating for Meituan-W with a target price of 178.12 HKD [5][12][15] Core Insights - The overall performance of Meituan in Q4 2024 exceeded expectations, with revenue reaching 885 billion CNY, a year-on-year increase of 20% [9] - The core local business showed resilience, with revenue of 656 billion CNY in Q4 2024, up 19% year-on-year [9] - New business segments, particularly overseas expansion, are seeing positive developments, with new business revenue growing by 24% year-on-year [10] Summary by Sections Delivery Business - In Q4 2024, the delivery orders grew in the high single digits, with average order value (AOV) declining year-on-year but showing a reduced decline quarter-on-quarter [2] - The operational improvements and increased monetization rates helped offset the negative impact of AOV decline on revenue [2] - The macroeconomic environment continues to affect delivery order volumes and AOV, but there are structural opportunities for advertising revenue growth [2] Flash Purchase - Flash purchase orders are estimated to have increased by approximately 25% in Q4 2024, achieving profitability for the year [3] - The convenience of instant retail is stimulating consumer demand, particularly in lower-tier markets [3] - Revenue growth is expected to outpace order growth, contributing significantly to long-term profits [3] In-store and Travel Services - Orders in the in-store and travel segment are projected to grow over 65% year-on-year in 2024, with record highs in annual transaction users and active merchants [4] - The introduction of live streaming and promotional activities is enhancing merchant operations and marketing efficiency [4] - The organizational adjustments and the launch of the Meituan membership system are expected to improve customer acquisition and transaction frequency in this segment [4] Financial Projections - The report forecasts a revenue of 337.6 billion CNY for 2024, with a year-on-year growth of 21.99% [12] - Adjusted net profit for 2024 is projected at 35.8 billion CNY, reflecting a significant year-on-year increase of 158.43% [12] - The estimated earnings per share for 2024 is 5.86 CNY, with a projected increase in subsequent years [12][14]
美团-W(03690):24Q4点评:核心主业好于预期,海外加大投入
Orient Securities· 2025-04-09 14:28
Investment Rating - The investment rating for Meituan is "Buy" (maintained) with a target price of 178.12 HKD [5][12]. Core Insights - The overall performance of Meituan in Q4 2024 exceeded expectations, with revenue reaching 885 billion CNY, a year-on-year increase of 20% [9]. - The core local business showed resilience, with revenue of 656 billion CNY in Q4 2024, up 19% year-on-year [9]. - New business segments, particularly in overseas markets, are seeing positive developments with a revenue increase of 24% year-on-year [10]. Summary by Sections Delivery Business - In Q4 2024, the delivery orders grew in the high single digits, with an improvement in average order profit year-on-year. The average order value (AOV) decreased year-on-year but the decline was less severe compared to the previous quarter [2]. - The operational efficiency is expected to improve with the trial of social security plans for delivery riders starting in Q2 [2]. Flash Purchase - The flash purchase segment achieved profitability in 2024, with a 25% year-on-year increase in orders. The growth is driven by increased convenience in instant retail and expansion in lower-tier markets [3]. In-store and Travel - The in-store and travel segment saw over 65% year-on-year growth in order volume in 2024, with record highs in annual transaction users and active merchants [4]. - The revenue growth slightly outpaced the gross transaction value (GTV) growth, indicating effective marketing strategies [4]. Financial Projections - Revenue for 2024 is projected at 337.59 billion CNY, with a year-on-year growth of 21.99%. The adjusted net profit is expected to reach 35.81 billion CNY, reflecting a significant recovery from previous losses [12][14]. - The company’s valuation is estimated at 10,882 billion HKD, with specific valuations for different segments: 3.5x PS for delivery, 13.2x PE for in-store and travel, and 0.6x P/GMV for new businesses [15].
吉利汽车:新车上市促进3月销量实现较高增长-20250409
Orient Securities· 2025-04-09 14:28
Investment Rating - The report maintains a "Buy" rating for Geely Automobile [5] Core Views - Geely's March sales showed significant growth, with total sales reaching 232,200 units, a year-on-year increase of 53.9% and a month-on-month increase of 13.3%. The sales of new energy vehicles reached 119,700 units, up 167.2% year-on-year [7] - The report forecasts EPS for 2025-2027 to be 1.27, 1.50, and 1.84 RMB respectively, maintaining a target price of 20.55 HKD based on a PE ratio of 15 times [2] - The report highlights the launch of new models and the advancement in intelligent driving technology, which are expected to enhance sales performance [7] Financial Forecasts - Revenue is projected to grow from 179,204 million RMB in 2023 to 414,141 million RMB in 2027, with a compound annual growth rate (CAGR) of 16.5% [4] - Operating profit is expected to increase from 3,806 million RMB in 2023 to 17,395 million RMB in 2027, reflecting a CAGR of 23.3% [4] - Net profit attributable to the parent company is forecasted to rise from 5,308 million RMB in 2023 to 18,526 million RMB in 2027, with a notable increase of 213.3% in 2024 [4] Sales Performance - Geely's brand sales in March reached 191,500 units, a year-on-year increase of 62.0%, with the Galaxy series achieving a remarkable 290.3% growth [7] - The report indicates that Geely's sales growth is expected to outperform the industry average, which saw a 10% increase in March [7] Model Launches and Innovations - The report details the launch of several new models, including the Galaxy series and the Zeekr brand, which are expected to contribute significantly to sales in 2025 [7] - The introduction of the L3 level intelligent driving technology is highlighted as a strategic move to enhance Geely's competitive edge in the market [7]
力诺药包(301188):动态更新:股权激励指引方向,持续回购增强信心
Orient Securities· 2025-04-09 14:05
力诺药包 301188.SZ 公司研究 | 动态跟踪 股价(2025年04月08日) 16.31 元 目标价格 18.60 元 52 周最高价/最低价 19.28/10.78 元 总股本/流通 A 股(万股) 23,245/23,245 A 股市值(百万元) 3,791 国家/地区 中国 行业 建材 报告发布日期 2025 年 04 月 09 日 买入 (维持) | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现 | -10.33 | -2.68 | 7.09 | -2.3 | | 相对表现 | -4.24 | 4.76 | 10.74 | -5.53 | | 沪深 300 | -6.09 | -7.44 | -3.65 | 3.23 | 冯孟乾 fengmengqian@orientsec.com.cn 执业证书编号:S0860523070003 股权激励指引方向,持续回购增强信心 ——力诺药包动态更新 核心观点 力诺药包动态跟踪 —— 股权激励指引方向,持续回购增强信心 盈利预测与投资建议 ⚫ 调整公司 2024-2026 ...
吉利汽车(00175):新车上市促进3月销量实现较高增长
Orient Securities· 2025-04-09 13:18
Investment Rating - The report maintains a "Buy" rating for Geely Automobile [5] Core Views - Geely's March sales showed significant growth, with total sales reaching 232,200 units, a year-on-year increase of 53.9% and a month-on-month increase of 13.3%. The sales of new energy vehicles reached 119,700 units, up 167.2% year-on-year [7] - The company is expected to launch five new energy models in 2025, enhancing its product matrix across various segments [7] - The target price is set at 20.55 HKD, based on a 15x PE valuation for 2025 [2] Financial Forecasts - The forecasted EPS for 2025-2027 is 1.27, 1.50, and 1.84 CNY respectively, with a target price of 19.05 CNY [2] - Revenue is projected to grow from 179,204 million CNY in 2023 to 414,141 million CNY in 2027, reflecting a compound annual growth rate (CAGR) of 16.5% [4][8] - Operating profit is expected to increase from 3,806 million CNY in 2023 to 17,395 million CNY in 2027, with a significant growth rate of 100.8% in 2024 [4][8] Sales Performance - Geely's brand sales in March reached 191,500 units, a year-on-year increase of 62.0% [7] - The Galaxy series saw a remarkable sales increase of 290.3% year-on-year in March [7] - Lynk & Co's sales also grew by 28.6% year-on-year, with the Lynk 900 model set to launch soon [7] Market Position - Geely's market capitalization is approximately 140,685 million HKD, with a total share capital of 1,007,770,000 shares [5] - The company is positioned within the automotive and components industry in China [5]